(Q33372951)

26 July 2017

title

Phase I clinical trial of bortezomib in combination with gemcitabine in patients with advanced solid tumors (English)

1 reference

26 July 2017

main subject

phase I clinical trial

0 references

Leonard J Appleman

2

0 references

author name string

David P Ryan

1

1 reference

26 July 2017

Thomas Lynch

3

1 reference

26 July 2017

Jeffrey G Supko

4

1 reference

26 July 2017

Panagiotis Fidias

5

1 reference

26 July 2017

Jeffrey W Clark

6

1 reference

26 July 2017

Mayer Fishman

7

1 reference

26 July 2017

Andrew X Zhu

8

1 reference

26 July 2017

Peter C Enzinger

9

1 reference

26 July 2017

Oscar Kashala

10

1 reference

26 July 2017

James Cusack

11

1 reference

26 July 2017

Joseph P Eder

12

1 reference

26 July 2017

language of work or name

English

0 references

publication date

1 November 2006

1 reference

26 July 2017

1 reference

26 July 2017

volume

107

1 reference

26 July 2017

issue

10

1 reference

26 July 2017

page(s)

2482-2489

1 reference

The cyclosome, a large complex containing cyclin-selective ubiquitin ligase activity, targets cyclins for destruction at the end of mitosis

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22264

Interaction with cyclin-dependent kinases and PCNA modulates proteasome-dependent degradation of p21

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22264

7 January 2021

Cut8, essential for anaphase, controls localization of 26S proteasome, facilitating destruction of cyclin and Cut2

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22264

7 January 2021

Turnover of cyclin E by the ubiquitin-proteasome pathway is regulated by cdk2 binding and cyclin phosphorylation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22264

7 January 2021

Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22264

7 January 2021

The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22264

7 January 2021

Proteasome inhibitor-induced apoptosis of B-chronic lymphocytic leukaemia cells involves cytochrome c release and caspase activation, accompanied by formation of an approximately 700 kDa Apaf-1 containing apoptosome complex

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22264

7 January 2021

An essential role for NF-kappaB in preventing TNF-alpha-induced cell death

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22264

7 January 2021

Suppression of TNF-alpha-induced apoptosis by NF-kappaB

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22264

7 January 2021

TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappaB

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22264

7 January 2021

Schedule-dependent molecular effects of the proteasome inhibitor bortezomib and gemcitabine in pancreatic cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22264

7 January 2021

Chemosensitization of pancreatic cancer by inhibition of the 26S proteasome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22264

7 January 2021

A phase 2 study of bortezomib in relapsed, refractory myeloma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22264

7 January 2021

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22264

7 January 2021

Decreased resistance to gemcitabine (2',2'-difluorodeoxycitidine) of cytosine arabinoside-resistant myeloblastic murine and rat leukemia cell lines: role of altered activity and substrate specificity of deoxycytidine kinase

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22264

7 January 2021

Role of NF-kappaB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22264

7 January 2021

Effects of the proteasome inhibitor bortezomib alone and in combination with chemotherapy in the A549 non-small-cell lung cancer cell line

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22264

7 January 2021

Proteasome inhibition sensitizes non-small-cell lung cancer to gemcitabine-induced apoptosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22264

7 January 2021

Induction of cell cycle arrest and apoptosis by the proteasome inhibitor PS-341 in Hodgkin disease cell lines is independent of inhibitor of nuclear factor-kappaB mutations or activation of the CD30, CD40, and RANK receptors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22264

7 January 2021

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22264

7 January 2021

Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22264

7 January 2021

The evaluation of gemcitabine in resistant or relapsing multiple myeloma, phase II: a Southwest Oncology Group study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22264

7 January 2021

Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22264

7 January 2021

Identifiers

DOI

10.1002/CNCR.22264

1 reference

26 July 2017

1 reference